
Teva appoints new president and chief executive
pharmafile | May 10, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | BMS, Jeremy Levin, Teva
Ex-BMS head Dr Jeremy Levin has been appointed president and chief executive of Teva.
Prior to joining Teva, Levin, who resides in Israel, was a member of the senior management team at Bristol-Myers Squibb, as senior vice president of Strategy, Alliances and Transactions.
He was responsible for the company’s global and ‘String of Pearls’ strategies, as well as M&A, licensing, divestitures, and corporate and academic alliances. At the same time, Levin served as president and director of two wholly-owned BMS subsidiaries.
Before joining BMS, Levin served as the global head of Strategic Alliances at Novartis Institutes of Biomedical Research, where he managed alliances with academia and biotechnology, and established strategic collaborations.
In addition, Levin has served on the executive committees and boards of numerous internationally renowned bioscience, biotechnology, venture fund and research organisations.
Related Content

Teva’s Ajovy significantly reduces migraine in children and adolescents
Teva’s Ajovy (fremanezumab) has demonstrated significant reduction in monthly migraine and headache days in children …

Teva announces positive results from trial of AJOVY for migraine
Teva has announced positive results from the phase 4 PEARL study of AJOVY (fremanezumab), its …

Elekta and BMS partner for digital treatment for melanoma
Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan …






